Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering ...
Allurion Technologies to initiate Allurion Balloon with GLP-1 agonists study
Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...
Le Lézard3d
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
Allurion Technologies, Inc. ("Allurion" or the "Company") , a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain ...
Allurion to sell 900,000 shares at $5.23 in registered direct offering
Allurion Technologies (ALUR) announced that it has entered into a definitive securities purchase agreement with certain institutional investors ...
Nasdaq4d
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today ...
Nasdaq3d
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...
Investing4d
Allurion to study balloon and GLP-1 therapy combo
NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a medical device company with a market capitalization of $17.7 million focused on addressing obesity, announced today its plan to conduct a ...
Investing4d
Allurion to study balloon and GLP-1 therapy combo
NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a medical device company with a market capitalization of $17.7 million focused on addressing obesity, announced today its plan to conduct ...
Morningstar4d
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination ...